Submit Manuscript  

Article Details


Isoliquiritigenin (ISL) and its Formulations: Potential Antitumor Agents

[ Vol. 26 , Issue. 37 ]

Author(s):

Ting-Ting Zhao, Yu-Qing Xu, Hui-Min Hu, Hai-Bin Gong* and Hai-Liang Zhu*   Pages 6786 - 6796 ( 11 )

Abstract:


Isoliquiritigenin (2’,4’,4-trihydroxychalcone, ISL) is one of the most important chalcone compounds which is mainly derived from licorice root and many other plants. It exhibits a remarkable range of potent biological and pharmacological activities such as antioxidative, antitumor, antiaging, anti-inflammatory, anti-diabetic activities, etc. Numerous research teams have demonstrated that ISL posseses the ability to carry out antigrowth and proliferation in various cancer cells in vitro and in vivo. Meanwhile, the underlying mechanisms of ISL that inhibit cancer cell proliferation have not been well explored. However, the poor bioavailability and low water-soluble limit its clinical application. This review aims at providing a comprehensive overview of the pharmacology antitumor activity of ISL and its mechanisms in different malignancy especially in breast cancer cell line and summarize developments of formulation utilized to overcome the barrier between its delivery characteristics and application in clinics over the past 20 years.

Keywords:

Isoliquiritigenin, antitumor, breast cancer, mechanisms, signaling pathway, formulation.

Affiliation:

State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023, State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210023



Read Full-Text article